EUVIMEDEUVIMED entdecken
Crossref

Regional Differences in Clinical Presentation and Prognosis of Patients With Post–Sustained Virologic Response Hepatocellular Carcinoma

Hidenori Toyoda, Mounika Kanneganti, Jonathan Melendez-Torres, Neehar D Parikh, Prasun K Jalal, Federico Piñero, Manuel Mendizabal, Ezequiel Ridruejo, Hugo Cheinquer, Andrea Casadei-Gardini, Arndt Weinmann, Markus Peck-Radosavljevic und 25 weitere

Clinical Gastroenterology and Hepatology · 2024

DOI: 10.1016/j.cgh.2023.06.026 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Gastroenterology and Hepatology, 2024. Verfasst von Hidenori Toyoda und 36 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Ogaki Municipal Hospital, Ogaki, Japan. Electronic address: hmtoyoda@spice.ocn.ne.jp. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Hepatitis C, Chronic. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 28 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND & AIMS: Widespread use of direct-acting antivirals for hepatitis C virus infection has been paralleled with increased numbers of patients with hepatocellular carcinoma (HCC) after achieving sustained virologic response (post-SVR HCC) worldwide. Few data compare regional differences in the presentation and prognosis of patients with post-SVR HCC. METHODS: We identified patients with advanced fibrosis (F3/F4) who developed incident post-SVR HCC between March 2015 and October 2021 from 30 sites in Europe, North America, South America, the Middle East, South Asia, East Asia, and Southeast Asia. We compared patient demographics, liver dysfunction, and tumor burden by region. We compared overall survival by region using Kaplan-Meier analysis and identified factors associated with survival using multivariable Cox regression analysis. RESULTS: Among 8796 patients with advanced fibrosis or cirrhosis who achieved SVR, 583 (6.6%) developed incident HCC. There was marked regional variation in the proportion of patients detected by surveillance (range: 59.5%-100%), median maximum tumor diameter (range, 1.8-5.0 cm), and the proportion with multinodular HCC (range, 15.4%-60.8%). The prognosis of patients highly varied by region (hazard ratio range, 1.82-9.92), with the highest survival rates in East Asia, North America, and South America, and the lowest survival rates in the Middle East and South Asia. After adjusting for geographic region, HCC surveillance was associated with early stage detection (Barcelona Clinic Liver Cancer stage 0/A, 71.0% vs 21.3%; P < .0001) and lower mortality rates (adjusted hazard ratio, 0.29; 95% CI, 0.18-0.46). CONCLUSIONS: Clinical characteristics, including early stage detection, and prognosis of post-SVR HCC differed significantly across geographic regions. Surveillance utilization appears to be a high-yield intervention target to improve prognosis among patients with post-SVR HCC globally.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsHepatitis C, ChronicHumansAntiviral AgentsSustained Virologic ResponseLiver CirrhosisPrognosisHepacivirusRisk Factors

Stichwörter der Autor:innen

Hepatitis C Virus InfectionHepatocellular CarcinomaPrognosisSurveillanceSustained Virologic Response

Substanzen

Antiviral Agents

Autor:innen und Institutionen

  • Department of Gastroenterology, Ogaki Municipal Hospital, Ogaki, Japan. Electronic address: hmtoyoda@spice.ocn.ne.jp.
  • Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas.
  • Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan.
  • Division of Abdominal Transplantation, Department of Medicine, Baylor College of Medicine, Houston, Texas.
  • Hospital Universitario Austral, School of Medicine, Austral University, Buenos Aires, Argentina.
  • Centro de Educación Medica e Investigaciones Clinicas, Norberto Quirno, Buenos Aires, Argentina.

Zitieren

APA

Toyoda, H., Kanneganti, M., Melendez-Torres, J., Parikh, N. D., Jalal, P. K., Piñero, F., Mendizabal, M., Ridruejo, E., Cheinquer, H., Casadei-Gardini, A., Weinmann, A., Peck-Radosavljevic, M., Dufour, J. F., Radu, P., Shiha, G., Soliman, R., Sarin, S. K., Kumar, M., Wang, J. H., …, & Johnson, P. J. (2024). Regional Differences in Clinical Presentation and Prognosis of Patients With Post–Sustained Virologic Response Hepatocellular Carcinoma. Clinical Gastroenterology and Hepatology. https://doi.org/10.1016/j.cgh.2023.06.026

Vancouver

Toyoda H, Kanneganti M, Melendez-Torres J, Parikh ND, Jalal PK, Piñero F, et al. Regional Differences in Clinical Presentation and Prognosis of Patients With Post–Sustained Virologic Response Hepatocellular Carcinoma. Clinical Gastroenterology and Hepatology. 2024. doi:10.1016/j.cgh.2023.06.026

BibTeX
@article{Toyoda2024,
  author = {Toyoda, Hidenori and Kanneganti, Mounika and Melendez-Torres, Jonathan and Parikh, Neehar D and Jalal, Prasun K and Piñero, Federico and Mendizabal, Manuel and Ridruejo, Ezequiel and Cheinquer, Hugo and Casadei-Gardini, Andrea and Weinmann, Arndt and Peck-Radosavljevic, Markus and Dufour, Jean-Francois and Radu, Pompilia and Shiha, Gamal and Soliman, Riham and Sarin, Shiv K and Kumar, Manoj and Wang, Jing-Houng and Tangkijvanich, Pisit and Sukeepaisarnjaroen, Wattana and Atsukawa, Masanori and Uojima, Haruki and Nozaki, Akito and Nakamuta, Makoto and Takaguchi, Koichi and Hiraoka, Atsushi and Abe, Hiroshi and Matsuura, Kentaro and Watanabe, Tsunamasa and Shimada, Noritomo and Tsuji, Kunihiko and Ishikawa, Toru and Mikami, Shigeru and Itobayashi, Ei and Singal, Amit G and Johnson, Philip J},
  title = {Regional Differences in Clinical Presentation and Prognosis of Patients With Post–Sustained Virologic Response Hepatocellular Carcinoma},
  journal = {Clinical Gastroenterology and Hepatology},
  year = {2024},
  doi = {10.1016/j.cgh.2023.06.026}
}
Kostenlos starten →